MannKind (MNKD)
(Delayed Data from NSDQ)
$4.23 USD
+0.05 (1.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.22 -0.01 (-0.24%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MNKD 4.23 +0.05(1.20%)
Will MNKD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MNKD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNKD
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings
MNKD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
Other News for MNKD
MNKD Makes Notable Cross Below Critical Moving Average
MannKind management to meet with Oppenheimer
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)
MannKind Repays Certain Debt Obligations
MannKind repays certain debt obligations